메뉴 건너뛰기




Volumn 20, Issue 11, 2018, Pages 2515-2522

Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?

Author keywords

atherosclerosis; cardiovascular outcomes; glucose; heart failure; IL 1 ; immune cells; inflammaging; insulin; ketone bodies; low grade inflammation; metaflammation; sodium glucose cotransporter (SGLT) 2 inhibitors; type 2 diabetes; uric acid

Indexed keywords

3 HYDROXYBUTYRIC ACID; HEMOGLOBIN A1C; INTERLEUKIN 1BETA; KETONE BODY; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID;

EID: 85052947600     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13488     Document Type: Review
Times cited : (99)

References (88)
  • 1
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 2
    • 85034766786 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657
    • (2017) N Engl J Med , vol.377 , pp. 644-657
    • Neal, B.1    Perkovic, V.2    Mahaffey, K.W.3
  • 3
    • 85014886914 scopus 로고    scopus 로고
    • Report from the 2nd cardiovascular outcome trial (CVOT) summit of the diabetes and cardiovascular disease (D&CVD) EASD study group
    • Schnell O, Standl E, Catrinoiu D, et al. Report from the 2nd cardiovascular outcome trial (CVOT) summit of the diabetes and cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2017;16:35
    • (2017) Cardiovasc Diabetol , vol.16 , pp. 35
    • Schnell, O.1    Standl, E.2    Catrinoiu, D.3
  • 4
    • 84979544369 scopus 로고    scopus 로고
    • Analyses of results from cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis
    • Mannucci E, Mosenzon O, Avogaro A. Analyses of results from cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis. Diabetes Care. 2016;39:S196-S204
    • (2016) Diabetes Care , vol.39 , pp. S196-S204
    • Mannucci, E.1    Mosenzon, O.2    Avogaro, A.3
  • 5
    • 85047995723 scopus 로고    scopus 로고
    • Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
    • Kosiborod M, Birkeland KI, Cavender MA, et al. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. Diabetes Obes Metab. 2018;20:1983-1987
    • (2018) Diabetes Obes Metab , vol.20 , pp. 1983-1987
    • Kosiborod, M.1    Birkeland, K.I.2    Cavender, M.A.3
  • 6
    • 85047499725 scopus 로고    scopus 로고
    • Lower cardiovascular risk associated with SGLT-2i in >400,000 patients: the CVD-REAL 2 study
    • Kosiborod M, Lam CSP, Kohsaka S, et al. Lower cardiovascular risk associated with SGLT-2i in >400,000 patients: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;pii: S0735-1097(18):33528-33529. https://doi.org/10.1016/j.jacc.2018.03.009
    • (2018) J Am Coll Cardiol , vol.pii: S0735-1097 , Issue.18 , pp. 33528-33529
    • Kosiborod, M.1    Lam, C.S.P.2    Kohsaka, S.3
  • 7
    • 85019731757 scopus 로고    scopus 로고
    • Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in ew users of sodium-glucose cotransporter-2 inhibitors)
    • Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in ew users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249-259
    • (2017) Circulation. , vol.136 , pp. 249-259
    • Kosiborod, M.1    Cavender, M.A.2    Fu, A.Z.3
  • 8
    • 85042796850 scopus 로고    scopus 로고
    • Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
    • Usman MS, Siddiqi TJ, Memon MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:495-502
    • (2018) Eur J Prev Cardiol , vol.25 , pp. 495-502
    • Usman, M.S.1    Siddiqi, T.J.2    Memon, M.M.3
  • 9
    • 85017172965 scopus 로고    scopus 로고
    • Mechanisms linking empagliflozin to cardiovascular and renal protection
    • Perrone-Filardi P, Avogaro A, Bonora E, et al. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017;241:450-456
    • (2017) Int J Cardiol , vol.241 , pp. 450-456
    • Perrone-Filardi, P.1    Avogaro, A.2    Bonora, E.3
  • 10
    • 85041180129 scopus 로고    scopus 로고
    • How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial
    • Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356-363
    • (2018) Diabetes Care , vol.41 , pp. 356-363
    • Inzucchi, S.E.1    Zinman, B.2    Fitchett, D.3
  • 11
    • 85041232661 scopus 로고    scopus 로고
    • Mortality reduction in EMPA-REG OUTCOME trial: beyond the antidiabetes effect
    • Suissa S. Mortality reduction in EMPA-REG OUTCOME trial: beyond the antidiabetes effect. Diabetes Care. 2018;41:219-223
    • (2018) Diabetes Care , vol.41 , pp. 219-223
    • Suissa, S.1
  • 12
    • 85073764370 scopus 로고    scopus 로고
    • Are the cardiovascular (CV) risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional CV risk factors?
    • Broedl UC, Fitchett D, Coleman RL, et al. Are the cardiovascular (CV) risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional CV risk factors? Can J Diabetes. 2017;41:S5
    • (2017) Can J Diabetes , vol.41 , pp. S5
    • Broedl, U.C.1    Fitchett, D.2    Coleman, R.L.3
  • 13
    • 84975853831 scopus 로고    scopus 로고
    • CV protection in the EMPA-REG OUTCOME trial: a "Thrifty Substrate" hypothesis
    • Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "Thrifty Substrate" hypothesis. Diabetes Care. 2016;39:1108-1114
    • (2016) Diabetes Care , vol.39 , pp. 1108-1114
    • Ferrannini, E.1    Mark, M.2    Mayoux, E.3
  • 14
    • 84964608804 scopus 로고    scopus 로고
    • Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients
    • Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes. 2016;65:1190-1195
    • (2016) Diabetes , vol.65 , pp. 1190-1195
    • Ferrannini, E.1    Baldi, S.2    Frascerra, S.3
  • 17
    • 0029008947 scopus 로고
    • Insulin, ketone bodies, and mitochondrial energy transduction
    • Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 1995;9:651-658
    • (1995) FASEB J , vol.9 , pp. 651-658
    • Sato, K.1    Kashiwaya, Y.2    Keon, C.A.3
  • 18
    • 84975775560 scopus 로고    scopus 로고
    • The failing heart relies on ketone bodies as a fuel
    • Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698-705
    • (2016) Circulation , vol.133 , pp. 698-705
    • Aubert, G.1    Martin, O.J.2    Horton, J.L.3
  • 19
    • 84908294192 scopus 로고    scopus 로고
    • Metabolic impairment in heart failure: the myocardial and systemic perspective
    • Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol. 2014;64:1388-1400
    • (2014) J Am Coll Cardiol , vol.64 , pp. 1388-1400
    • Doehner, W.1    Frenneaux, M.2    Anker, S.D.3
  • 21
    • 85019577699 scopus 로고    scopus 로고
    • Effects of ketogenic diets on cardiovascular risk factors: evidence from animal and human studies
    • E517.
    • Kosinski C, Jornayvaz FR. Effects of ketogenic diets on cardiovascular risk factors: evidence from animal and human studies. Nutrients. 2017;9:E517
    • (2017) Nutrients , vol.9
    • Kosinski, C.1    Jornayvaz, F.R.2
  • 22
    • 84920587151 scopus 로고    scopus 로고
    • β-hydroxybutyrate: much more than a metabolite
    • Newman JC, Verdin E. β-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract. 2014;106:173-181
    • (2014) Diabetes Res Clin Pract , vol.106 , pp. 173-181
    • Newman, J.C.1    Verdin, E.2
  • 23
    • 85006759447 scopus 로고    scopus 로고
    • Impact of intermittent fasting on health and disease processes
    • Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. Ageing Res Rev. 2017;39:46-58
    • (2017) Ageing Res Rev , vol.39 , pp. 46-58
    • Mattson, M.P.1    Longo, V.D.2    Harvie, M.3
  • 24
    • 60749090581 scopus 로고    scopus 로고
    • The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
    • Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev. 2009;59:293-315
    • (2009) Brain Res Rev , vol.59 , pp. 293-315
    • Maalouf, M.1    Rho, J.M.2    Mattson, M.P.3
  • 25
    • 84924356420 scopus 로고    scopus 로고
    • The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
    • Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263-269
    • (2015) Nat Med , vol.21 , pp. 263-269
    • Youm, Y.H.1    Nguyen, K.Y.2    Grant, R.W.3
  • 26
    • 85048218284 scopus 로고    scopus 로고
    • Anti-oxidant and anti-inflammatory activity of ketogenic diet: new perspectives for neuroprotection in Alzheimer's disease
    • Pinto A, Bonucci A, Maggi E, Corsi M, Businaro R. Anti-oxidant and anti-inflammatory activity of ketogenic diet: new perspectives for neuroprotection in Alzheimer's disease. Antioxidants (Basel). 2018;7:E63
    • (2018) Antioxidants (Basel) , vol.7
    • Pinto, A.1    Bonucci, A.2    Maggi, E.3    Corsi, M.4    Businaro, R.5
  • 27
    • 84870950694 scopus 로고    scopus 로고
    • Intermittent fasting during Ramadan attenuates proinflammatory cytokines and immune cells in healthy subjects
    • Faris MA, Kacimi S, Al-Kurd RA, et al. Intermittent fasting during Ramadan attenuates proinflammatory cytokines and immune cells in healthy subjects. Nutr Res. 2012;32:947-955
    • (2012) Nutr Res , vol.32 , pp. 947-955
    • Faris, M.A.1    Kacimi, S.2    Al-Kurd, R.A.3
  • 28
    • 85018941706 scopus 로고    scopus 로고
    • Role of NLRP3 inflammasomes in atherosclerosis
    • Karasawa T, Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb. 2017;24:443-451
    • (2017) J Atheroscler Thromb , vol.24 , pp. 443-451
    • Karasawa, T.1    Takahashi, M.2
  • 29
    • 0037180771 scopus 로고    scopus 로고
    • Inflammation in atherosclerosis
    • Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874
    • (2002) Nature. , vol.420 , pp. 868-874
    • Libby, P.1
  • 30
  • 31
    • 85020772837 scopus 로고    scopus 로고
    • IL-1β inhibition in cardiovascular complications associated to diabetes mellitus
    • Peiró C, Lorenzo Ó, Carraro R, Sánchez-Ferrer CF. IL-1β inhibition in cardiovascular complications associated to diabetes mellitus. Front Pharmacol. 2017;8:363
    • (2017) Front Pharmacol , vol.8 , pp. 363
    • Peiró, C.1    Lorenzo, Ó.2    Carraro, R.3    Sánchez-Ferrer, C.F.4
  • 32
    • 85032443928 scopus 로고    scopus 로고
    • Inflammageing and metaflammation: the yin and yang of type 2 diabetes
    • Prattichizzo F, De Nigris V, Spiga R, et al. Inflammageing and metaflammation: the yin and yang of type 2 diabetes. Ageing Res Rev. 2018;41:1-17
    • (2018) Ageing Res Rev , vol.41 , pp. 1-17
    • Prattichizzo, F.1    De Nigris, V.2    Spiga, R.3
  • 33
    • 85030468815 scopus 로고    scopus 로고
    • Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition
    • Calder PC, Bosco N, Bourdet-Sicard R, et al. Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. Ageing Res Rev. 2017;40:95-119
    • (2017) Ageing Res Rev , vol.40 , pp. 95-119
    • Calder, P.C.1    Bosco, N.2    Bourdet-Sicard, R.3
  • 34
    • 85012115740 scopus 로고    scopus 로고
    • Inflammation, metaflammation and immunometabolic disorders
    • Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177-185
    • (2017) Nature , vol.542 , pp. 177-185
    • Hotamisligil, G.S.1
  • 35
    • 39149141607 scopus 로고    scopus 로고
    • Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation
    • Epub 2007 November 29.
    • Forsythe CE, Phinney SD, Fernandez ML, et al. Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids. 2008;43(1):65-77. Epub 2007 November 29
    • (2008) Lipids , vol.43 , Issue.1 , pp. 65-77
    • Forsythe, C.E.1    Phinney, S.D.2    Fernandez, M.L.3
  • 36
    • 79955693448 scopus 로고    scopus 로고
    • The inflammasome in atherosclerosis and type 2 diabetes
    • 81ps17.
    • Masters SL, Latz E, O'Neill LA. The inflammasome in atherosclerosis and type 2 diabetes. Sci Transl Med. 2011;3:81ps17
    • (2011) Sci Transl Med , vol.3
    • Masters, S.L.1    Latz, E.2    O'Neill, L.A.3
  • 37
    • 77951800951 scopus 로고    scopus 로고
    • NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
    • Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361
    • (2010) Nature , vol.464 , pp. 1357-1361
    • Duewell, P.1    Kono, H.2    Rayner, K.J.3
  • 38
    • 85013422749 scopus 로고    scopus 로고
    • Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease
    • eaai8700.
    • Wei M, Brandhorst S, Shelehchi M, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017;9:eaai8700
    • (2017) Sci Transl Med , vol.9
    • Wei, M.1    Brandhorst, S.2    Shelehchi, M.3
  • 39
    • 84937392878 scopus 로고    scopus 로고
    • A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan
    • Brandhorst S, Choi IY, Wei M, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015;22:86-99
    • (2015) Cell Metab , vol.22 , pp. 86-99
    • Brandhorst, S.1    Choi, I.Y.2    Wei, M.3
  • 40
    • 84901325457 scopus 로고    scopus 로고
    • The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages
    • Rahman M, Muhammad S, Khan MA, et al. The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun. 2014;5:3944
    • (2014) Nat Commun , vol.5 , pp. 3944
    • Rahman, M.1    Muhammad, S.2    Khan, M.A.3
  • 41
    • 85042042148 scopus 로고    scopus 로고
    • Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin
    • Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab. 2018;20:1321-1326
    • (2018) Diabetes Obes Metab , vol.20 , pp. 1321-1326
    • Polidori, D.1    Iijima, H.2    Goda, M.3    Maruyama, N.4    Inagaki, N.5    Crawford, P.A.6
  • 42
    • 79952240405 scopus 로고    scopus 로고
    • Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
    • Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest. 2011;121:1163-1173
    • (2011) J Clin Invest , vol.121 , pp. 1163-1173
    • Lukasova, M.1    Malaval, C.2    Gille, A.3    Kero, J.4    Offermanns, S.5
  • 43
    • 84872166360 scopus 로고    scopus 로고
    • Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor
    • Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339:211-214
    • (2013) Science , vol.339 , pp. 211-214
    • Shimazu, T.1    Hirschey, M.D.2    Newman, J.3
  • 44
    • 34047218122 scopus 로고    scopus 로고
    • HDAC inhibitors as anti-inflammatory agents
    • Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol. 2007;150:829-831
    • (2007) Br J Pharmacol , vol.150 , pp. 829-831
    • Adcock, I.M.1
  • 45
    • 34748850786 scopus 로고    scopus 로고
    • Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress
    • Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab. 2007;6:280-293
    • (2007) Cell Metab , vol.6 , pp. 280-293
    • Schulz, T.J.1    Zarse, K.2    Voigt, A.3    Urban, N.4    Birringer, M.5    Ristow, M.6
  • 46
    • 85028647707 scopus 로고    scopus 로고
    • A ketogenic diet extends longevity and healthspan in adult mice
    • Roberts MN, Wallace MA, Tomilov AA, et al. A ketogenic diet extends longevity and healthspan in adult mice. Cell Metab. 2017;26:539-546.e5
    • (2017) Cell Metab , vol.26 , pp. 539-546.e5
    • Roberts, M.N.1    Wallace, M.A.2    Tomilov, A.A.3
  • 48
    • 2342647592 scopus 로고    scopus 로고
    • Long-term calorie restriction is highly effective in reducing the risk of atherosclerosis in humans
    • Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk of atherosclerosis in humans. Proc Natl Acad Sci USA. 2004;101:6659-6663
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 6659-6663
    • Fontana, L.1    Meyer, T.E.2    Klein, S.3    Holloszy, J.O.4
  • 49
    • 0036307135 scopus 로고    scopus 로고
    • A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men
    • Sharman MJ, Kraemer WJ, Love DM, et al. A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J Nutr. 2002;132:1879-1885
    • (2002) J Nutr , vol.132 , pp. 1879-1885
    • Sharman, M.J.1    Kraemer, W.J.2    Love, D.M.3
  • 50
    • 85038255405 scopus 로고    scopus 로고
    • A metabolomic signature of acute caloric restriction
    • Collet TH, Sonoyama T, Henning E, et al. A metabolomic signature of acute caloric restriction. J Clin Endocrinol Metab. 2017;102:4486-4495
    • (2017) J Clin Endocrinol Metab , vol.102 , pp. 4486-4495
    • Collet, T.H.1    Sonoyama, T.2    Henning, E.3
  • 51
    • 84975789692 scopus 로고    scopus 로고
    • Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism
    • Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032-2038
    • (2016) Diabetes , vol.65 , pp. 2032-2038
    • Briand, F.1    Mayoux, E.2    Brousseau, E.3
  • 52
    • 33646948539 scopus 로고    scopus 로고
    • Calorie restriction mimetics: an emerging research field
    • Ingram DK, Zhu M, Mamczarz J, et al. Calorie restriction mimetics: an emerging research field. Aging Cell. 2006;5:97-108
    • (2006) Aging Cell , vol.5 , pp. 97-108
    • Ingram, D.K.1    Zhu, M.2    Mamczarz, J.3
  • 53
    • 85041815856 scopus 로고    scopus 로고
    • Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
    • Sugizaki T, Zhu S, Guo G, et al. Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality. NPJ Aging Mech Dis. 2017;3:12
    • (2017) NPJ Aging Mech Dis , vol.3 , pp. 12
    • Sugizaki, T.1    Zhu, S.2    Guo, G.3
  • 54
    • 84911942671 scopus 로고    scopus 로고
    • The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity
    • Oelze M, Kröller-Schön S, Welschof P, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014;9:e112394
    • (2014) PLoS One , vol.9
    • Oelze, M.1    Kröller-Schön, S.2    Welschof, P.3
  • 55
    • 85021409196 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
    • Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370-385
    • (2017) Redox Biol , vol.13 , pp. 370-385
    • Steven, S.1    Oelze, M.2    Hanf, A.3
  • 56
    • 85045051294 scopus 로고    scopus 로고
    • Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes
    • Birnbaum Y, Bajaj M, Yang HC, Ye Y. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes. Cardiovasc Drugs Ther. 2018;32:135-145
    • (2018) Cardiovasc Drugs Ther , vol.32 , pp. 135-145
    • Birnbaum, Y.1    Bajaj, M.2    Yang, H.C.3    Ye, Y.4
  • 57
    • 85046143333 scopus 로고    scopus 로고
    • Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice
    • Tahara A, Takasu T. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. Eur J Pharmacol. 2018;830:68-75
    • (2018) Eur J Pharmacol , vol.830 , pp. 68-75
    • Tahara, A.1    Takasu, T.2
  • 58
    • 85009349867 scopus 로고    scopus 로고
    • The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-/- Mice
    • Leng W, Ouyang X, Lei X, et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-/- Mice. Mediat Inflamm. 2016;2016:6305735
    • (2016) Mediat Inflamm , vol.2016 , pp. 6305735
    • Leng, W.1    Ouyang, X.2    Lei, X.3
  • 59
    • 85026920030 scopus 로고    scopus 로고
    • The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice
    • E1704.
    • Nakatsu Y, Kokubo H, Bumdelger B, et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci. 2017;18:E1704
    • (2017) Int J Mol Sci , vol.18
    • Nakatsu, Y.1    Kokubo, H.2    Bumdelger, B.3
  • 60
    • 85038024525 scopus 로고    scopus 로고
    • Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages
    • Prattichizzo F, De Nigris V, Mancuso E, et al. Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. Redox Biol. 2018;15:170-181
    • (2018) Redox Biol , vol.15 , pp. 170-181
    • Prattichizzo, F.1    De Nigris, V.2    Mancuso, E.3
  • 61
    • 85009810559 scopus 로고    scopus 로고
    • Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation
    • Dror E, Dalmas E, Meier DT, et al. Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol. 2017;18:283-292
    • (2017) Nat Immunol , vol.18 , pp. 283-292
    • Dror, E.1    Dalmas, E.2    Meier, D.T.3
  • 63
    • 84908555003 scopus 로고    scopus 로고
    • SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
    • Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391-404
    • (2014) Biopharm Drug Dispos , vol.35 , pp. 391-404
    • Chino, Y.1    Samukawa, Y.2    Sakai, S.3
  • 64
    • 85017476975 scopus 로고    scopus 로고
    • Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-κB signaling pathway in HepG2 cells
    • Spiga R, Marini MA, Mancuso E, et al. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-κB signaling pathway in HepG2 cells. Arterioscler Thromb Vasc Biol. 2017;37:1241-1249
    • (2017) Arterioscler Thromb Vasc Biol , vol.37 , pp. 1241-1249
    • Spiga, R.1    Marini, M.A.2    Mancuso, E.3
  • 65
    • 85009502184 scopus 로고    scopus 로고
    • Soluble uric acid activates the NLRP3 inflammasome
    • Braga TT, Forni MF, Correa-Costa M, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep. 2017;7:39884
    • (2017) Sci Rep , vol.7 , pp. 39884
    • Braga, T.T.1    Forni, M.F.2    Correa-Costa, M.3
  • 66
    • 85020077721 scopus 로고    scopus 로고
    • SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice
    • Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137-149
    • (2017) EBioMedicine , vol.20 , pp. 137-149
    • Xu, L.1    Nagata, N.2    Nagashimada, M.3
  • 67
    • 85010842028 scopus 로고    scopus 로고
    • Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
    • Lee T-M, Chang N-C, Lin S-Z. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298-310
    • (2017) Free Radic Biol Med , vol.104 , pp. 298-310
    • Lee, T.-M.1    Chang, N.-C.2    Lin, S.-Z.3
  • 68
    • 0037109184 scopus 로고    scopus 로고
    • Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress
    • Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-2072
    • (2002) Circulation , vol.106 , pp. 2067-2072
    • Esposito, K.1    Nappo, F.2    Marfella, R.3
  • 69
    • 85019737787 scopus 로고    scopus 로고
    • Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
    • Ferrannini E, Baldi S, Frascerra S, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40:771-776
    • (2017) Diabetes Care , vol.40 , pp. 771-776
    • Ferrannini, E.1    Baldi, S.2    Frascerra, S.3
  • 70
    • 84937635957 scopus 로고    scopus 로고
    • Antidiabetic agents: potential anti-inflammatory activity beyond glucose control
    • Scheen AJ, Esser N, Paquot N. Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab. 2015;41:183-194
    • (2015) Diabetes Metab , vol.41 , pp. 183-194
    • Scheen, A.J.1    Esser, N.2    Paquot, N.3
  • 71
    • 84982132601 scopus 로고    scopus 로고
    • The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
    • Pujadas G, De Nigris V, Prattichizzo F, La Sala L, Testa R, Ceriello A. The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine. 2017;56:509-520
    • (2017) Endocrine , vol.56 , pp. 509-520
    • Pujadas, G.1    De Nigris, V.2    Prattichizzo, F.3    La Sala, L.4    Testa, R.5    Ceriello, A.6
  • 72
    • 80051795160 scopus 로고    scopus 로고
    • Cardiovascular effects of DPP-4 inhibition: beyond GLP-1
    • Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55:10-16
    • (2011) Vascul Pharmacol , vol.55 , pp. 10-16
    • Fadini, G.P.1    Avogaro, A.2
  • 73
    • 85044585390 scopus 로고    scopus 로고
    • Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascularendothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
    • Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascularendothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep. 2018;8:5276
    • (2018) Sci Rep , vol.8 , pp. 5276
    • Mancini, S.J.1    Boyd, D.2    Katwan, O.J.3
  • 74
    • 85018253813 scopus 로고    scopus 로고
    • SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor
    • Ye Y, Bajaj M, Yang H-C, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31:119-132
    • (2017) Cardiovasc Drugs Ther , vol.31 , pp. 119-132
    • Ye, Y.1    Bajaj, M.2    Yang, H.-C.3    Perez-Polo, J.R.4    Birnbaum, Y.5
  • 75
    • 85029568219 scopus 로고    scopus 로고
    • Antiinflammatory therapy with canakinumab for atherosclerotic disease
    • Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131
    • (2017) N Engl J Med , vol.377 , pp. 1119-1131
    • Ridker, P.M.1    Everett, B.M.2    Thuren, T.3
  • 76
    • 84890473570 scopus 로고    scopus 로고
    • Stabilization of atherosclerotic plaques: an update
    • Ylä-Herttuala S, Bentzon JF, Daemen M, et al. Stabilization of atherosclerotic plaques: an update. Eur Heart J. 2013;34:3251-3258
    • (2013) Eur Heart J , vol.34 , pp. 3251-3258
    • Ylä-Herttuala, S.1    Bentzon, J.F.2    Daemen, M.3
  • 78
    • 84891770455 scopus 로고    scopus 로고
    • Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease
    • Madhumitha H, Mohan V, Deepa M, Babu S, Aravindhan V. Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease. Cardiovasc Diabetol. 2014;13:1
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 1
    • Madhumitha, H.1    Mohan, V.2    Deepa, M.3    Babu, S.4    Aravindhan, V.5
  • 79
    • 79955535643 scopus 로고    scopus 로고
    • Macrophages in the pathogenesis of atherosclerosis
    • Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355
    • (2011) Cell , vol.145 , pp. 341-355
    • Moore, K.J.1    Tabas, I.2
  • 80
    • 84859210770 scopus 로고    scopus 로고
    • Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
    • IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213
    • (2012) Lancet , vol.379 , pp. 1205-1213
    • Sarwar, N.1    Butterworth, A.S.2
  • 81
    • 2642535951 scopus 로고    scopus 로고
    • Inflammation as a cardiovascular risk factor
    • Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2-II10
    • (2004) Circulation , vol.109 , pp. II2-II10
    • Willerson, J.T.1    Ridker, P.M.2
  • 82
    • 0034704893 scopus 로고    scopus 로고
    • C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
    • Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843
    • (2000) N Engl J Med , vol.342 , pp. 836-843
    • Ridker, P.M.1    Hennekens, C.H.2    Buring, J.E.3    Rifai, N.4
  • 83
    • 84894456906 scopus 로고    scopus 로고
    • Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study
    • Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63:1115-1123
    • (2014) Diabetes , vol.63 , pp. 1115-1123
    • Lowe, G.1    Woodward, M.2    Hillis, G.3
  • 84
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3
  • 85
    • 85020040943 scopus 로고    scopus 로고
    • Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms
    • Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Med. 2017;130:S30-S39
    • (2017) Am J Med , vol.130 , pp. S30-S39
    • Staels, B.1
  • 86
    • 85030848386 scopus 로고    scopus 로고
    • SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
    • Bell RM, Yellon DM. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol. 2018;6:435-437
    • (2018) Lancet Diabetes Endocrinol. , vol.6 , pp. 435-437
    • Bell, R.M.1    Yellon, D.M.2
  • 87
    • 84937817781 scopus 로고    scopus 로고
    • Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels
    • Sjöström CD, Hashemi M, Sugg J, Ptaszynska A, Johnsson E. Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes Obes Metab. 2015;17:809-812
    • (2015) Diabetes Obes Metab , vol.17 , pp. 809-812
    • Sjöström, C.D.1    Hashemi, M.2    Sugg, J.3    Ptaszynska, A.4    Johnsson, E.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.